Raymond James downgraded shares of Leap Therapeutics (NASDAQ:LPTX) from an outperform rating to a market perform rating in a research report sent to investors on Friday morning, BayStreet.CA reports.
Several other brokerages also recently weighed in on LPTX. ValuEngine upgraded Leap Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Leap Therapeutics from a buy rating to a hold rating in a research note on Tuesday, October 15th.
Shares of LPTX stock traded up $0.04 during midday trading on Friday, hitting $0.77. The company had a trading volume of 4,267 shares, compared to its average volume of 218,344. The company’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $1.54. Leap Therapeutics has a 52-week low of $0.57 and a 52-week high of $4.05. The stock has a market cap of $15.59 million, a price-to-earnings ratio of -0.31 and a beta of 2.47. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.39 and a quick ratio of 1.39.
Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Thursday, November 14th. The company reported ($0.33) earnings per share for the quarter, meeting the consensus estimate of ($0.33). Analysts anticipate that Leap Therapeutics will post -1.43 EPS for the current year.
Several institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in shares of Leap Therapeutics by 63.3% in the first quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after buying an additional 606,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Leap Therapeutics by 183.4% during the second quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock worth $994,000 after purchasing an additional 359,320 shares in the last quarter. BlackRock Inc. boosted its position in Leap Therapeutics by 40.0% during the second quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock worth $61,000 after purchasing an additional 9,782 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Leap Therapeutics during the second quarter worth $42,000. Finally, A.R.T. Advisors LLC purchased a new stake in Leap Therapeutics during the second quarter worth $28,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
See Also: QQQ ETF
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.